Last reviewed · How we verify
I.V HBIG
At a glance
| Generic name | I.V HBIG |
|---|---|
| Sponsor | Green Cross Corporation |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Treatment of Patients With Chronic Hepatitis B With Hepatitis B Immunoglobulins (PHASE2)
- A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj. (PHASE3)
- Impact of Hepatitis B Immunoglobulins in Patients With Chronic Hepatitis B on Hepatocellular Carcinoma - a Proof of Concept Study (NA)
- HBV-associated Liver Transplant(LT) Patients by IV Injecting GC1102 (PHASE2, PHASE3)
- A Phase 1 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- I.V HBIG CI brief — competitive landscape report
- I.V HBIG updates RSS · CI watch RSS
- Green Cross Corporation portfolio CI